How are Structure Therapeutics’ ADSs related to the Ordinary Shares in this Form 4?

Structure Therapeutics’ American Depositary Shares each represent three Ordinary Shares. The option’s exercise price is based on the ADS trading price, but the underlying security described in the Form 4 is Ordinary Shares, not ADSs themselves.

Structure Therapeutics director granted 39,453 options

Structure Therapeutics director Eric Dobmeier received a new stock option grant covering 39,453 Ordinary Shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Structure Therapeutics director Eric Dobmeier received a new stock option grant covering 39,453 Ordinary Shares. The option has an exercise price of $15.00 per share, set at the fair market value on the grant date based on the trading price of the company’s American Depositary Shares (ADSs).

The option vests in equal monthly installments over the 12 months following June 17, 2026, and will be fully vested no later than immediately before the company’s 2027 annual shareholder meeting. The option expires on June 16, 2036. Each ADS represents three Ordinary Shares. Following this grant, Dobmeier holds 39,453 options directly.

Insider Trade Summary

Grant/Award: 39,453 shares

Grant/Award 1 txn

Insider DOBMEIER ERIC

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	39,453	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 39,453 contracts (Direct)

Footnotes (3)

F1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Key Figures

Option grant size: 39,453 options Exercise price: $15.00 per share Shares after transaction: 39,453 options +3 more

6 metrics

Option grant size 39,453 options Share Option covering 39,453 Ordinary Shares

Exercise price $15.00 per share Option exercise price equals fair market value on grant date

Shares after transaction 39,453 options Total derivative securities following the grant

Expiration date June 16, 2036 Option expiration for this grant

Vesting schedule 12 monthly installments Vests over 12 months following June 17, 2026

ADS to Ordinary ratio 1 ADS : 3 Ordinary Shares Each ADS represents three Ordinary Shares

Key Terms

Share Option (right to buy), fair market value, American Depositary Shares ("ADSs"), vest in equal monthly installments, +1 more

5 terms

fair market value financial

"exercise price per share is equal to the fair market value per Ordinary Share"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

American Depositary Shares ("ADSs") financial

"based on the trading price of the Issuer's American Depositary Shares ("ADSs")"

American Depositary Shares (ADSs) are U.S.-listed certificates issued by a bank that represent ownership of a specified number of a foreign company’s ordinary shares, letting U.S. investors buy and sell those interests in U.S. dollars on American markets. They matter because they make investing in overseas companies as easy as buying a domestic stock—streamlining currency, settlement, and recordkeeping—while still exposing investors to foreign-market risks like exchange rates and local regulations.

vest in equal monthly installments financial

"The shares vest in equal monthly installments over the 12 months"

expiration date financial

"expiration_date: "2036-06-16T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Eric Dobmeier report in the latest Form 4 for GPCR?

Eric Dobmeier reported receiving a stock option grant for 39,453 Ordinary Shares of Structure Therapeutics. The option is a compensation-related award, not an open-market purchase or sale, and gives him the right to buy shares at a fixed exercise price.

What is the exercise price of Eric Dobmeier’s new GPCR stock options?

The exercise price of the new stock options is $15.00 per Ordinary Share. This price equals the fair market value on the grant date, based on the trading price of Structure Therapeutics’ American Depositary Shares at that time.

How do Eric Dobmeier’s GPCR options vest over time?

The options vest in equal monthly installments over the 12 months following June 17, 2026. They will in any case be fully vested immediately before Structure Therapeutics’ 2027 annual shareholder meeting, assuming the vesting conditions continue to be met.

When do Eric Dobmeier’s GPCR stock options expire?

The reported stock options expire on June 16, 2036. After that expiration date, Eric Dobmeier would no longer be able to exercise these options to buy Ordinary Shares of Structure Therapeutics at the stated exercise price of $15.00 per share.

How many GPCR options does Eric Dobmeier hold after this transaction?

After this transaction, Eric Dobmeier holds 39,453 stock options directly. Each option relates to one Ordinary Share, and these options represent his position from this specific grant as reported in the Form 4 insider filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 05:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOBMEIER ERIC

(Last)

(First)

(Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (right to buy)	$15⁽¹⁾	06/17/2026		A		39,453		⁽²⁾	06/16/2036	Ordinary Shares	39,453⁽³⁾	$0	39,453	D

Explanation of Responses:

1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,

3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

	/s/ Jun Yoon, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR